Drug Trial Radar · NCT05907668
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
May 15, 2023
Primary completion
Jul 25, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of 24 weeks of treatment with batoclimab in adult participants with biochemically documented hyperthyroidism due to GD who have failed to achieve euthyroidism on antithyroid drugs (ATDs).
Conditions
- Graves Disease
Interventions
IMVT-1401 (batoclimab)Drug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Normalization of Free Triiodothyronine (FT3) and Free Thyroxine (FT4), or Have FT3 and/or FT4 Below the Lower Limit of Normal (LLN) at Week 24 Without Increase in ATD Dose Compared to BaselineTime frame: At Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site Number - 6505
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.